Lilly brain cancer drug promising in small study
Key points
- Eli Lilly and Co. said on Tuesday a midstage study of a brain cancer drug helped shrink tumors with minimal side effects.
- Lilly said the compound, enzastaurin, is the first targeted agent to enter into late-stage clinical development.
- The phase II study included 92 patients with recurrent brain tumors who had failed more than one round of chemotherapy.
- Preliminary results from the study showed 20 percent to 25 percent of patients responded to the drug, with the most common side effect being thrombocytopenia, or low platelet count.
Eli Lilly and Co. said on Tuesday a midstage study of a brain cancer drug helped shrink tumors with minimal side effects.
Lilly said the compound, enzastaurin, is the first targeted agent to enter into late-stage clinical development. The pill is aimed at stopping blood flow to tumors in glioblastoma, a type of brain cancer that affects the central nervous system.
The phase II study included 92 patients with recurrent brain tumors who had failed more than one round of chemotherapy.
Preliminary results from the study showed 20 percent to 25 percent of patients responded to the drug, with the most common side effect being thrombocytopenia, or low platelet count.
Lilly said final results from the mid-stage study are expected by 2006, and the company is designing a late-stage study of the drug to confirm its safety and effectiveness in a bigger pool of patients.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsCost of cancer drugs varies widely based on who's paying
Uninsured cancer patients are asked to pay anywhere from two to 43 times what Medicare would pay for chemotherapy drugs, according to a new study from the University of North Carolina at Chapel Hill. Researchers led by…
8 April 2015
News3-D snapshot of protein highlights potential drug target for breast cancer
The genome of a cell is under constant attack, suffering DNA damage that requires an army of repair mechanisms to keep the cell healthy and alive. Understanding the behavior of the enzymes defending these assaults helps…
19 March 2015
NewsNCCS pioneers new drug regimen which reduces toxicities for renal cancer patients
A study led by the Genitourinary (GU) oncology team at National Cancer Centre Singapore (NCCS) has revealed conclusive results in reducing toxicities for Asian patients with metastatic renal cell carcinoma (mRCC) or…
